Protocol summary

Study aim
Comparison of the effect of ointment prepared from Myrtle and wild-saffron medicinal plants with anti-hemorrhoid ointment on the symptoms of grade I and II internal hemorrhoids.
Design
This three-blind randomized clinical trial will be conducted on 60 men and women with grade I and II hemorrhoids.
Settings and conduct
Patients referred to Tabriz medical centers will be assigned to two intervention and control groups using random block design. The intervention group will receive herbal ointment and the control will receive anti-hemorrhoid ointment twice a day for 4 week. With the colorectal clinical evaluation questionnaire, the amount of pain, itching, swelling, bleeding, anal discomfort and the negative effect of hemorrhoids on people's sense of health and well-being will be investigated.
Participants/Inclusion and exclusion criteria
Entry requirements; Patients in the age group of 17 to 70, literate and suffering from 1 and 2 degree hemorrhoids Non-entry condition; Use of systemic steroidal and non-steroidal anti-inflammatory drugs and analgesic treatments; and anti hemorrhoid (for one month before the study) and the use of anticoagulant drugs; The need for surgery to treat hemorrhoids Suffering from inflammatory infectious diseases of the digestive tract or colorectal cancer; Previous use of laser or use of phlebutonic drug to treat hemorrhoids one week before from entering the study or participating in another interventional study
Intervention groups
The people of the intervention group, including 60 men and women with first and second degree hemorrhoids, will receive herbal ointment. Also, the control group will include 60 men and women with first and second grade hemorrhoids, who will receive anti-hemorrhoid ointment.
Main outcome variables
formulation of anti-hemorrhoid ointment Determining the effect of this ointment on the symptoms of grade I and II internal hemorrhoids

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20221013056160N1
Registration date: 2022-12-18, 1401/09/27
Registration timing: prospective

Last update: 2022-12-18, 1401/09/27
Update count: 0
Registration date
2022-12-18, 1401/09/27
Registrant information
Name
Negar Valizadeh
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 41 3330 7795
Email address
n.valizadeh@rifr-ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2023-01-11, 1401/10/21
Expected recruitment end date
2023-09-22, 1402/06/31
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Formulation, physicochemical evaluation and comparison of the effect of ointment prepared from Myrtus communis L. and Colchicum automnale L. with anti-hemorrhoid ointment on the symptoms of grade I and II internal hemorrhoids: a three-blind controlled clinical trial
Public title
Investigating the effect of ointment prepared from Myrtus communis L. and Colchicum automnale L. for the treatment of grade I and II internal hemorrhoids
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Clients with first and second grade hemorrhoids who have been diagnosed with clinical symptoms and confirmation from a general surgeon. Patients should be in the age group of 17 to 70 years. Hemorrhoids of the clients are not caused by systemic diseases such as hypertension. Presence of hemorrhoid symptoms for at least more than 6 days Ability to read and write
Exclusion criteria:
Use of systemic steroidal and non-steroidal anti-inflammatory drugs and analgesic treatments The use of systemic steroidal and non-steroidal anti-inflammatory drugs and analgesic and anti-hemorrhoid treatments (for one month before the study) and the use of anticoagulant drugs. The need for a surgical method to treat hemorrhoids (with the approval of a gastroenterologist and using clinical and colonoscopy tests) Patients with problems such as anorectal abscess, fistula, tuberculosis, herpes, varicella (confirmed by clinical tests or colonoscopy) Infectious inflammatory diseases of the digestive tract or colorectal cancer (according to the patient's statement) Previous use of laser or use of phlebotonic medicine to treat hemorrhoids one week before entering the study (according to the patient's statement) Participation in another interventional study
Age
From 17 years old to 70 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Care provider
  • Investigator
Sample size
Target sample size: 60
Randomization (investigator's opinion)
Randomized
Randomization description
Random allocation rule This method represents a large block for the entire sample volume, which means that the balance in the number of people It will be allocated to each of the groups at the end of the study. For this purpose, he first determined a total sample size, then randomly assigned a group of them to group A and the rest to group B.
Blinding (investigator's opinion)
Triple blinded
Blinding description
This three-blind randomized clinical trial will be conducted on 60 men and women with grade I and II hemorrhoids referring to health and treatment centers in Tabriz city. Eligible people will be assigned to two intervention and control groups using random block. In this study, the researcher, participant and clinical caregiver will not know the type of intervention received by the participants.
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of TAbriz University of Medical Sciences
Street address
Tabriz University, Building No. 2 of Medical Sciences, Research and Technology Vice-Chancellor, 3rd floor
City
Tabriz
Province
East Azarbaijan
Postal code
۵۱۶۶۶۱۶۴۷۱
Approval date
2022-09-12, 1401/06/21
Ethics committee reference number
IR.TBZMED.REC.1401.516

Health conditions studied

1

Description of health condition studied
grade I and II internal hemorrhoids
ICD-10 code
ICD-10 code description

Primary outcomes

1

Description
Investigating the amount of pain with the colo-rectal clinical treatment evaluation questionnaire
Timepoint
This questionnaire will be completed once before the start of the study and then in the first, second and fourth weeks, and once after the end of the intervention, in the eighth week after the start of the treatment.
Method of measurement
(CORECTS= Colo-Rectal Evaluation of Clinical Therapeutics Scale)

2

Description
Investigating the amount of itching around the anus with the colorectal clinical treatment evaluation questionnaire
Timepoint
This questionnaire will be completed once before the start of the study and then in the first, second and fourth weeks, and once after the end of the intervention, in the eighth week after the start of the treatment.
Method of measurement
(CORECTS= Colo-Rectal Evaluation of Clinical Therapeutics Scale)

3

Description
Investigating the amount of bleeding with the colo-rectal clinical treatment evaluation questionnaire
Timepoint
This questionnaire will be completed once before the start of the study and then in the first, second and fourth weeks, and once after the end of the intervention, in the eighth week after the start of the treatment.
Method of measurement
(CORECTS= Colo-Rectal Evaluation of Clinical Therapeutics Scale)

Secondary outcomes

1

Description
The questionnaire (WHOQOL-BREF) will be used to measure the quality of life
Timepoint
This questionnaire will be completed before the start of the study, in the fourth week after the intervention and in the eighth week after the start of the treatment.
Method of measurement
Questionnaire (WHOQOL-BREF)

Intervention groups

1

Description
Intervention group: Intervention group: The intervention group includes 60 men and women with first and second degree hemorrhoids, referring to medical centers in Tabriz city, who will receive the herbal ointment.
Category
Treatment - Drugs

2

Description
Control group: The control group will include 60 men and women with first and second grade hemorrhoids in the same centers that will receive anti-hemorrhoid ointment or suppositories.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Imam Sajjad Hospital
Full name of responsible person
Babak Abri Aghdam
Street address
East side of Pasdaran highway,Educational complex of Islamic Azad University of Tabriz, Imam Sajjad Hospital, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5157944533
Phone
+98 41 3196 6000
Email
info@iaut.ac.ir
Web page address
https://tabriz.iau.ir/fa

2

Recruitment center
Name of recruitment center
Amiralmoemenin Hospital
Full name of responsible person
Babak Abri Aghdam
Street address
Above Mantash station,Quds St., Amiralmoemenin Hospital,Tabriz, iran
City
Tabriz
Province
East Azarbaijan
Postal code
5137844787
Phone
+98 41 9101 0920
Email
hospital.ali1@gmail.com
Web page address
http://alihospital.ir/

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Applied Pharmaceutical Research Center, Tabriz University of Medical Sciences
Full name of responsible person
Hamed Hamishehkar
Street address
University Street, Research and Development Complex of Tabriz University of Medical Sciences, Applied Pharmaceutical Research Center, Tabriz, Iran.
City
Tabriz
Province
East Azarbaijan
Postal code
0000000000
Phone
+98 41 3335 7314
Email
info.medfac@tbzmed.ac.ir
Web page address
https://medfac.tbzmed.ac.ir/
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Applied Pharmaceutical Research Center, Tabriz University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Babak Abri Aghdam
Position
Assistant professor
Latest degree
Subspecialist
Other areas of specialty/work
General Surgery
Street address
Unit D, 5th Floor, Hakim Building, , Between Shariati and Taleghani Intersection, , Pastor New Street, Tabriz, Iran.
City
Tabriz
Province
East Azarbaijan
Postal code
0000000000
Phone
+98 41 3557 3306
Email
babak756a@yahoo.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Hamed Hamishehkar
Position
Associate professor
Latest degree
Specialist
Other areas of specialty/work
Medical Pharmacy
Street address
Applied Pharmaceutical Research Center, Tabriz University of Medical Sciences, University Street, Tabriz.
City
Tabriz
Province
East Azarbaijan
Postal code
0000000000
Phone
+98 41 3336 3311
Fax
+98 41 3336 3231
Email
hamishehkar.hamed@gmail.com
Web page address
https://darc-fa.tbzmed.ac.ir/?PageID=31

Person responsible for updating data

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Hamed Hamishehkar
Position
Associate professor
Latest degree
Specialist
Other areas of specialty/work
Medical Pharmacy
Street address
Applied Pharmaceutical Research Center, Tabriz University of Medical Sciences, University Street, Tabriz.
City
Tabriz
Province
East Azarbaijan
Postal code
5165665811
Phone
+98 41 3337 8163
Fax
+98 41 3336 3231
Email
hamishehkar.hamed@gmail.com
Web page address
https://darc-fa.tbzmed.ac.ir/

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Title and more details about the data/document
All data is potentially shareable after de-identifying individuals
When the data will become available and for how long
The access period starts 12 months after the results are published
To whom data/document is available
Academic and scientific institutions
Under which criteria data/document could be used
Mentioning the source should be used in all stages of their research and writing the article.
From where data/document is obtainable
Dr. Hamed Hamishehkar Associate Professor of Faculty of Pharmacy in Tabriz Mobile phone: 00989143169252 Email: hamishehkar.hamed@gmail.com
What processes are involved for a request to access data/document
Immediately after the request, the effect will be arranged.
Comments
Loading...